At Ironshore Pharmaceuticals & Development, Inc. we use proprietary drug-delivery technology to develop improved versions of existing drug products.
Ironshore Pharmaceuticals & Development, Inc. is a biopharmaceutical company whose mission is to develop innovative, patient-centric treatment options, utilizing its proprietary DELEXIS® technology, to improve the lives of patients and caregivers. Based in Grand Cayman, Ironshore is responsible for managing all intellectual property, and directing all research, development and manufacturing activities for its drug candidates. Ironshore Pharmaceuticals Inc., based in Philadelphia, PA, is responsible for the sales, marketing and distribution of Ironshore’s products within the US. Both companies are wholly owned subsidiaries of Toronto-based Highland Therapeutics Inc.
Ironshore's lead compound, HLD200 (delayed-release and extended-release methylphenidate) is under development for the treatment of Attention-Deficit/Hyperactivity Disorder, or ADHD. A New Drug Application for HLD200 is currently being reviewed by the U.S. Food and Drug Administration.
HLD100, also under development for the treatment of ADHD, is expected to begin a pivotal Phase 3 trial in H2/2017.
US Head Office
1550 Liberty Ridge Dr.
Chesterbrook, PA 19087-5567
Main phone: 484-222-4930
Research & Development Headquarters
10 Market Street
Camana Bay, KY1-9006
MaRS Centre Heritage Building
101 College St, Suite HL20-2
Toronto, ON Canada M5G 1L7